Valuation : SANA AB

Market Cap 1.63B 170M 147M 138M 126M 236M 16.09B 236M 633M 8.25B 640M 626M 26.59B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.63B 170M 147M 138M 126M 236M 16.09B 236M 633M 8.25B 640M 626M 26.59B EV / Sales 2026 *
6.11x
EV / Sales 2027 * 4.2x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day-0.34%
1 week+1.72%
Current month+3.23%
1 month-12.00%
3 months-11.47%
6 months-19.00%
Current year-44.29%
1 week 11.22
Extreme 11.22
12.11
1 month 11.01
Extreme 11.01
14.39
Current year 11.01
Extreme 11.01
28.3
1 year 11
Extreme 11
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Buy

Founder

9,000 0.0065%
28/8/26 Buy

Chief Financial Officer

5,000 0.0036%
27/8/26 Buy

Director

4,188 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%+1.72%-10.94%+74.45% 170M
-1.79%-2.27%+43.23%+99.78% 67.98B
-2.06%-0.18%+39.67%+85.24% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
+0.33%+0.94%+26.48%+17.80% 25.74B
-1.46%+0.42%+23.61%-16.76% 20.09B
-2.96%-15.21%+216.20%+375.70% 17.16B
+0.65%-1.17%-6.67%+550.86% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.76%+0.40%+36.67%+171.69% 27.93B
Weighted average by Cap. -1.12%+0.18%+37.73%+141.82%

Financials

2026 *2027 *
Net sales 267M 27.91M 24.02M 22.6M 20.64M 38.61M 2.64B 38.72M 104M 1.35B 105M 103M 4.36B 388M 40.54M 34.88M 32.82M 29.98M 56.08M 3.83B 56.23M 150M 1.96B 152M 149M 6.33B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
04/09/26 SEK 11.81 -0.34% 213,293
03/09/26 SEK 11.85 +0.51% 386,459
02/09/26 SEK 11.79 -0.42% 275,288
01/09/26 SEK 11.84 +3.50% 456,496
31/08/26 SEK 11.44 -1.46% 602,594

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!